FY2024 EPS Estimates for SI-BONE Raised by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN) – Analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for SI-BONE in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($0.65) for the year, up from their prior estimate of ($0.69). The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share. Cantor Fitzgerald also issued estimates for SI-BONE’s FY2025 earnings at ($0.19) EPS.

SIBN has been the topic of a number of other reports. Truist Financial upped their target price on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a report on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $23.00.

SI-BONE Stock Down 0.7 %

SIBN stock opened at $16.52 on Thursday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE has a fifty-two week low of $11.70 and a fifty-two week high of $21.64. The stock’s 50 day simple moving average is $14.01 and its 200 day simple moving average is $14.42. The company has a market cap of $692.85 million, a P/E ratio of -17.96 and a beta of 1.16.

Hedge Funds Weigh In On SI-BONE

Several institutional investors and hedge funds have recently bought and sold shares of the company. Champlain Investment Partners LLC lifted its position in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after buying an additional 358,821 shares during the last quarter. Bellevue Group AG raised its stake in SI-BONE by 4.1% in the 3rd quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock valued at $20,189,000 after acquiring an additional 56,500 shares during the period. State Street Corp lifted its holdings in SI-BONE by 5.1% during the third quarter. State Street Corp now owns 1,081,871 shares of the company’s stock valued at $15,125,000 after purchasing an additional 52,972 shares during the last quarter. Wellington Management Group LLP boosted its position in SI-BONE by 3.5% during the third quarter. Wellington Management Group LLP now owns 1,028,238 shares of the company’s stock worth $14,375,000 after purchasing an additional 35,220 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of SI-BONE by 3.4% in the third quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock worth $12,921,000 after purchasing an additional 30,005 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

Insider Activity at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Anshul Maheshwari sold 2,439 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.68, for a total transaction of $30,926.52. Following the sale, the chief financial officer now owns 194,623 shares of the company’s stock, valued at approximately $2,467,819.64. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,348 shares of company stock valued at $356,349. 3.90% of the stock is owned by insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.